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Abstract
Background: Osteosarcoma is the most common type of primary bone tumor. The use of
aggressive chemotherapy has drastically improved the prognosis of the patients with non-
metastatic osteosarcomas, however the prognosis of the patients with metastasis is still very poor.
Then, new and more effective treatments for curing osteosarcoma, such as immunotherapy are
needed. Tumor-infiltrating lymphocytes (TIL) have been involved in the control of tumor
development and already assessed with success for the treatment of several cancers including
melanoma. While TIL represent a fascinating therapeutic approach in numerous malignant
pathologies, there is few report concerning adult bone-associated tumors including osteosarcoma.
Methods: Human TIL were isolated and characterized (phenotype, lytic activity) from twenty-
seven patients with bone-associated tumors (osteosarcoma, Ewing's sarcoma, giant cell tumor,
chondrosarcoma, plasmocytoma and bone metastases). Similar experiments were performed using
rat osteosarcoma model.
Results: While TIL with a main CD4+ profile were easily isolated from most of the tumor samples,
only TIL extracted from osteosarcoma were cytotoxic against allogeneic tumor cells. In all cases,
TIL lytic activity was significantly higher compared to autologous peripheral blood leukocytes.
Similar data were observed in rat osteosarcoma model where TIL were characterized by a main
CD4+ profile and high lytic activity against allogeneic and autologous tumor cells. Moreover, rat TIL
expansion was not accompanied by refractoriness to further activation stimulus mainly by tumor
antigens.
Conclusion: These results demonstrated that TIL therapy could be a very efficient strategy for
the treatment of adult osteosarcoma.
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Background
Primary or secondary malignant bone tumors represent a
major therapeutic challenge in medical oncology. Despite
efficiency of conventional treatments by chemo- and radi-
otherapy, long-term outcome of the patients suffering
from malignant bone tumors remains poor. Among them,
osteosarcoma is the most frequent primary bone tumor.
Indeed, the current strategy for the treatment of high-
grade osteosarcoma is based on neo-adjuvant chemother-
apy, delayed en-bloc wide resection and adjuvant chemo-
therapy adapted to the histologic profile of the tumor
tissues removed during surgery [1]. While marked
improvements in surgery and the development of differ-
ent regimens of multidrug chemotherapy over the past 25
years, the survival remains around 55 to 70% after 5 years
[2,3]. Furthermore, the prognosis is worse in the patients
with non-extremities localization, advancing age, radio-
induced osteosarcoma and those arising from Paget's dis-
ease of bone, representing 40% of the entire osteosarcoma
population. In addition, the patients with metastatic oste-
osarcoma at the time of diagnosis have poor survival sta-
tistics (30% at 5 years). All these findings suggest necessity
of establishing new therapeutic strategies to improve the
overall rate of survival, especially in high-risk sub-groups.
Among the potential new therapeutic strategies, immuno-
therapies are based on the up-regulation of the immune
response in tumor-bearing host. Two therapeutic
approaches can be distinguished: (i) active immunothera-
pies that elicit immune response against tumor cells in
tumor-bearing host (including pulsed dendritic cells and
cytokine treatments), (ii) passive or adoptive immuno-
therapies consist on the administration of ex vivo-
expanded tumor-specific cytotoxic immune cells repre-
sented by T lymphocytes. The identification of tumor-spe-
cific lymphocytes has resulted in new therapeutic
strategies based on mounting a sustained and effective
anti-tumor immune response [4,5]. It is theorized that the
infiltrating lymphoid represents a selected population of
cells which have preferentially migrated to the tumor sec-
ondary to an immune response. These T lymphocytes
termed tumor-infiltrating lymphocytes (TIL) are consid-
ered to be more specific in their immunological reactivity
to tumor cells than the non-infiltrating lymphocytes [6].
However, if the role of TIL has not been clearly defined,
TIL could recognized as a reactional mechanism against
tumor development. Moreover, their reduced response in
the tumor tissue may be due to the suppressive influence
under the tumor microenvironment. In this context, TIL
have been identified in numerous neoplasia, such as
melanoma [5-9], various carcinomas [10-17], myeloma
[18], pediatric tumors [19] and sarcomas [20-22] and the
therapeutic relevance of these TIL has been also docu-
mented in both animal models and clinical trials [23-28].
Unfortunatly, up to date, very few data is available on the
phenotypic and functional characterization of TIL isolated
from adult bone-associated tumors.
Because, in vitro studies on bone tumor infiltrating T lym-
phocytes are lacking, the goal of the present study is to
characterize the TIL derived from 27 adult human bone-
associated tumors as well as autologous peripheral blood
leukocytes (PBL) at the phenotypic and functional levels.
The therapeutic potential of TIL was then discussed for
osteosarcoma.
Methods
1) Patients
Twenty-seven bone-associated tumors [6 osteosarcomas,
2 Ewing's sarcomas, 2 chondrosarcomas, 7 giant cell
tumors (GCTs), 2 plasmocytomas, 4 bone metastases (2
from kidney origin, 2 form unknown origin) and 4 other
pathologies (1 chondromyxoid fibroma, 1 fibrous dyspla-
sia, 1 chordoma, 1 undifferentiated sarcoma)] from 27
patients [12 women (38 + 17.8 years, range: 17–75) and
15 men (47.9 + 19.2) years, range: 16–75)] were included
in the present study. All patients were treated in the
Department of Orthopedic Surgery of Nantes University
Hospital (France) between September 2004 and June
2005. Patients' characteristics were summarized in Table 1
("Additional file 1"). Written informed consent was
obtained before each patient was included in the study.
2) Cell lines
The rat osteosarcoma (UMR106), human osteosarcoma
(MG63, SaOS2), B lymphoma (Daudi) and leukemia
(K562) cell lines were purchased from the American Tis-
sue Cell Collection (USA). The rat osteosarcoma ROS 17/
2.8 cell line was a kind gift from Pr HJ Donahue (Penn
State University, USA). The tumor cell lines were culture-
din RPMI 1640 (Invitrogen, France) supplemented with
10% foetal calf serum (FCS) (Hyclone, Perbio, France).
The primary osteosarcoma was isolated from small tumor
fragment of rat osteosarcoma model described above.
Briefly, small tumor fragments were digested by 1 mg/mL
collagenase A (Boehringer Manheim) for 2 hours. The cell
suspensions obtained were then washed three times with
PBS and cultured in RPMI 1640 supplemented with 10%
FCS. The medium was changed twice a week and the
adherent osteosarcoma cells were harvested using a 0.05%
trypsin- 0.02% EDTA solution and subjected to the study.
3) Osteosarcoma rat model
The osteosarcoma was initially induced by a local injec-
tion of colloidal radioactive 144Cerium in rats [29]. The
tumor can be re-grafted and maintained in vivo for many
months; otherwise fragments were frozen until re-utiliza-
tion. This rat osteosarcoma model used in the present
study mimics the human pathology in terms of tumor
growth, bone involvements and lung metastases [30,31].
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4) Peripheral blood leukocytes (PBL) preparation and 
tumor-infiltrating lymphocytes (TIL) extraction
Both human and rat PBL were isolated from heparinized
peripheral blood after Ficoll-Hypaque (Eurobio, France)
gradient centrifugation. The human and rat PBL were
respectively cultured in RPMI 1640 supplemented with
10% FCS and 300 UI/ml IL-2 (Eurocetus, France) for 21
days and X-VIVO 15 supplemented with 900 UI/ml IL-2
for 14 days. Their phenotype and cytotoxic activity were
then analyzed according to the procedure described
below.
Human tumor specimens were directly received from the
operating room under sterile condition, minced with scis-
sors into 1 mm3 fragments and cultured immediately in
RPMI 1640 (Invitrogen) supplemented with 10% FCS
(Hyclone), 300 UI/ml IL-2 (Eurocetus) and antibiotics
mixture (100 UI/mL penicillin and 100 µg/mL streptomy-
cin). Half of medium was changed twice a week and TIL
were cultured for 21 days.
Rat tumor specimens were obtained from the model
described above, minced with scissors into 9 mm3 frag-
ments and subjected enzymatic digestion using 2 mg/mL
collagenase and 50 UI/mL hyaluronidase (Sigma-Aldrich,
France) for 2 hours. The cell suspension (106 cell/mL) was
filtrated using a 70 µm cell strainer. Then, enriched by
Ficoll-Hypaque gradient centrifugation and cultured in X-
VIVO 15 serum free-medium supplemented with 900 UI/
mL IL-2 and antibiotics mixture (100 UI/mL penicillin
and 100 µg/mL streptomycin). Half of medium was
changed twice a week and TIL were cultured for 14 days.
Both PBL and TIL were maintained at 37°C in a 5% CO2
humidified atmosphere.
5) Cytotoxicity assay
Target cells (UMR106, MG63, SaOS2, Daudi, K562,
ROS17/2.8 and primary autologous rat osteosarcoma
cells) were labeled with 10 µCi of Na2 51CrO4 (Amersham,
UK) for 1 hour at 37°C. Then, target cells were washed
three times with fresh culture medium. Lymphocytes (TIL
or PBL) were added at a different target/effector ratio (T/
E) of 1/12.5, 1/25 and 1/50. The plate was then incubated
for 4 hours at 37°C, and 100 µL of supernatant were
haversted for counting in a γ-counter. Maximal and spon-
tenous 51Cr-releases were determined by incubating the
target cells with 100 µL of detergent (Triton 1% in distil-
lated water) or 100 µL of culture medium, respectively.
Spontaneous release (SR) never exceeded 10% of maximal
release (MR). The percentage of specific chromium release
was calculated according to the following formula:
[(experimental release-SR)/(MR-SR)] × 100%].
6) Flow cytometric analysis
For phenotyping, lymphocytes (TIL or PBL) were stained
with conjugated monoclonal antibodies against CD3
(PE), CD4 (APC), CD8 (perCP), CD20 (FITC), CD45RA
(FITC), CD161 (PE). Monoclonal antibodies were pur-
chased from Becton Dickinson (France) (CD3, CD4, CD8
and CD20) and from Serotec (France) (CD161 and
CD45RA). Cell suspensions were then analyzed on a Bec-
ton Dickinson fluorescence-activated cell sorter. Ten thou-
sand scatter-gated cells were analyzed in each sample and
fluorescence profiles of the cells were determined with
logarithmic signal amplifiers.
7) Statistical analysis
All experiments were performed in triplicate. The mean
and SD was calculated for all conditions and compared by
an ANOVA test. Differences relative to a probability of
two-tailed P < 0.05 were considered significant
Results
1) Human TIL can be extracted from various human tumor 
biopsies and cultured
TIL were able to isolate successfully from small tumor
fragments (wet weight < 5 g) immediately after the biopsy
except for chondrosarcoma, fibrous dysplasia and 50% of
bone metastases (Table 1) and maintained for 3 weeks in
the presence of 300 UI/ml IL-2 for flow cytometric analy-
ses. Most of cultured TIL were mainly composed of CD3+
(range: 65%–99%) (Figure 1, hatched bars). TIL from
plasmocytomas showed preferentially CD4+ profile
(median: 64.4%) with minor CD8+ profile (median:
6.4%). Similarly, TIL from osteosarcomas were predomi-
nantly CD4+ (median: 49.9%) with second highest CD8+
sub-population (median: 15.5%). TIL isolated from
Ewing's sarcomas, GCTs and bone metastases are charac-
terized by almost same amount of CD4+ and CD8+ popu-
lations (around 50%) (Figure 1). A minor amount of
CD20+ and CD161+ cells were observed in all TIL without
correlation with tumor histology.
To compare PBL and TIL expanded from the same
patients, phenotypic analyses of PBL were also performed
in all included cases (Figure 1, dark bars). The amount of
CD8+ TIL was lower in plasmocytoma, Ewing's sarcoma
and osteosarcoma TIL compared to that of PBL (respec-
tively 88%, 58%, and 57%). A high amount of natural
killer (NK) CD161+ (43%) cells were detected in PBL from
Ewing's sarcoma-bearing patients in contrast to the others.
2) Human TIL isolated from osteosarcomas exert cytotoxic 
activity against allogeneic cell lines
To determine the cytotoxic activity of expanded TIL
against allogeneic cell lines, 51Cr-released assays were car-
ried out. The lytic patterns of TIL against Daudi and K562
cell lines that reflect LAK and NK activity, and against two
BMC Cancer 2005, 5:123 http://www.biomedcentral.com/1471-2407/5/123
Page 4 of 10
(page number not for citation purposes)
Phenotypic analysis of TIL isolated from human bone associated tumors compared with the phenotype of autologous PBLFigure 1
Phenotypic analysis of TIL isolated from human bone associated tumors compared with the phenotype of 
autologous PBL. TIL were isolated from tumor biopsies and cultured for 21 days in RPMI 1640 supplemented with 10% FCS 
and 300 UI/ml IL-2. Autologous PBL were isolated from peripheral blood samples after gradient density centrifugation and cul-
tured in the same conditions for 21 days. After the indicated culture period, the phenotype of TIL (hatched bars) and PBL (dark 
bars) were analyzed by flow cytometry. The percentages of positive cells are given as median value. Plasmocytoma, n = 2; 
Ewing's sarcoma, n = 2; giant cell tumor, n = 7; bone metastase, n = 4; osteosarcoma, n= 6.
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allogeneic osteosarcoma cell lines SaOS2 and MG63,
which exhibit respectively high and low osteoblastic dif-
ferentiation state were assessed. TIL amplified from plas-
tocytomas, Ewing's sarcomas and GCTs did not show any
lytic activity against all allogeneic cell lines tested (data
not shown). However, TIL extracted from osteosarcoma
biopsies were significantly cytotoxic against all cell lines
analyzed compared to matched autologous PBL (p < 0.01)
(Figure 2). The cytotoxic profiles against K562 and the
other cell lines were different along with T/E ratio. Indeed,
the magnitude of TIL cytotoxicity against K562 cells varied
from 50% to 70% respectively for a ratio T/E of 1/12.5 to
1/50. The magnitude of TIL lytic activity against Daudi,
SaOS2 and MG63 reached 20% for a ratio T/E of 1/12.5 to
65% for a ratio T/E of 1/50. In all osteosarcomas analyzed,
autologous PBL were weakly cytotoxic against the four all-
ogeneic cell lines, and no dose-response was observed in
autologous PBL cytotoxic activity (Figure 2).
3) TIL isolated from rat osteosarcoma showed a similar 
phenotype and lytic pattern to human TIL
TIL expanded from rat tumor biopsies revealed same phe-
notype as those of human osteosarcoma. Namely, rat TIL
were 90% CD3+, 50% CD4+ and 18% CD8+ in median
Comparison of cytotoxic activity between TIL isolated from human osteosarcomas and autologous PBLFigure 2
Comparison of cytotoxic activity between TIL isolated from human osteosarcomas and autologous PBL. TIL 
and autologous PBL were isolated from human osteosarcomas (n = 6). After 21 days of culture in RPMI 1640 supplemented 
with 10% FCS and 300 UI/ml IL-2, TIL and autologous PBL cytotoxic activities were determined using 51Cr-released assays. The 
cytotoxicity was measured against allogeneic cell lines including Daudi, K562 cell lines and two osteosarcoma cell lines, high 
(SaOS2) and low (MG63) osteoblastic differentiated osteosarcoma. ** p < 0.01; *** p < 0.001, TIL versus PBL cytotoxicity.
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value (Figure 3, hatched bars). Autologous PBL had an
inverse CD4+/CD8+ ratio with 16% CD4+ and 32% CD8+
cells in median value (Figure 3, dark bars).
51Cr-released assays also disclosed the similar lytic pattern
of rat TIL against autologous and allogeneic tumor cell
lines (UMR 106, ROS 17/2.8) to human TIL (Figure 4).
Moreover, this lytic activity was higher against autologous
tumor cells and UMR 106 (63% T/E of 1/50) compared to
ROS 17/2.8 cells (48% T/E of 1/50) (Figure 4).
To elucidate the capability of autologous tumor cells to
stimulate the proliferation of rat TIL, expanded TIL were
cultured with irradiated tumor cells. Figure 5 showed the
kinetic expansion of rat TIL without tumor antigens dur-
ing the first 23 days and with irradiated tumor cells in the
following term. TIL proliferation was characterized by
gradual expansion (more than 4-fold) in the first 3 weeks
culture and rapid proliferation reached 10-fold number
within following five days culture (Figure 5). TIL
expanded from rat osteosarcoma were very sensitive to the
tumor antigens expressed by autologous tumor cells.
These data demonstrated that TIL expanded from osteosa-
rcoma were very sensitive to the tumor antigens expressed
by autologous tumor cells.
Discussion
The present data demonstrated that TIL could be isolated
from the most of adult bone-associated tumors studied
Comparative analysis of TIL and autologous PBL phenotype is lated from rat o te sarcomaFigure 3
Comparative analysis of TIL and autologous PBL 
phenotype isolated from rat osteosarcoma. TIL were 
isolated from rat osteosarcoma biopsies (n = 8) by enzymatic 
treatment and cultured for 14 days in X-VIVO 15 supple-
mented with 900 UI/ml IL-2. Autologous PBL were isolated 
from peripheral blood samples after gradient density centrif-
ugation and cultured in the same conditions for 14 days. 
After the culture period, the phenotype of TIL (hatched bars) 
and PBL (dark bars) were analyzed by flow cytometry. The 
percentages of positive cells are given as median value.
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were determined using 51Cr-released assays. The cytotoxic-
ity was measured against autologous rat osteosarcoma cells 
and allogeneic rat osteosarcoma cell lines including UMR 106 
and ROS 17/2.8. * p < 0.05, TIL versus PBL cytotoxicity.
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(osteosarcomas, Ewing's sarcomas, GCTs, plasmocyto-
mas) except for chondrosarcoma, fibrous dysplasia and
50% of bone metastases; while only TIL extracted from
osteosarcomas demonstrated a lytic activity against allo-
geneic tumor cell lines. Moreover, TIL extracted from oste-
osarcoma biopsies were significantly cytotoxic against all
cell lines analyzed compared to matched autologous PBL.
These findings demonstrating the interest of expanded TIL
to target osteosarcoma cells.
Lymphocytes localized in a tumor foci could represent a
tumor-specific response of T lymphocytes associated for
one part to a non-specific component due to the
inflammatory infiltrate. In this context, the adoptive
transfer of specific-cytotoxic T cells has been already
shown to induce tumor rejection in several animal tumor
models [32,33]. Although isolation and characterization
of TIL have been successfully performed in human malig-
nant tumors [5-21], few data is available in the literature
about bone-associated tumors except for pediatric tumors
[34,35]. The presence of T lymphocytes in human osteosa-
rcoma tissues was previously studied by Trieb et al. by
immunohistochemical studies [36]. Phenotypic analyses
have revealed that these infiltrating lymphocytes into
osteosarcoma were 95% CD3+ and 68% CD8+ [36].
Rivoltini L et al. have also analyzed the phenotype of TIL
in 37 pediatric tumors, including 12 osteosarcomas and
demonstrated CD8+ predominancy [34]. The latter also
revealed that the lytic pattern of TIL against both alloge-
neic and autologous tumor cells were variable depend on
the histology. Rivoltini L et al. concluded, in 1992, that
TIL extracted from pediatric tumors were difficult to
expand at levels required for immunotherapy, however
they could be envisaged [34]. In our study, the phenotype
of TIL isolated from adult osteosarcomas are very similar
in all cases (two third of CD4+ and one third of CD8+) and
autologous PBL were weakly cytotoxic against the four all-
ogeneic cell lines tested. This discrepancy between TIL and
PBL could be explained by the homing processus of the
tumor-specific T lymphocytes to the tumor foci. Indeed,
recently, Haanen et al investigated the presence of TIL and
circulating Tumor Associated antigens(TAA)-T cells before
and after autologous tumor cell vaccination in metastatic
melanoma patients [35]. They demonstrated that in none
of the patients, TAA-specific T cells were found both in
tumor tissue and circulating blood at the same time. No
significant changes in the frequency and specificity circu-
lating TAA-specific T were found during the treatment
period in all patients while inside melanoma tissue, TAA-
specific TIL could be detected in 75% of tumor samples
analyzed. These data suggested that a possible homing
phenomenon of the tumor-specific T cell population to
the tumor site could contribute to the effectiveness of anti-
tumor immunity.
An experiment rat osteosarcoma model mimicking the
human pathology was used to elucidate the availability of
TIL in an autologous system. TIL extracted from rat tumor
biopsies demonstrated similar phenotype to human oste-
osarcoma TIL (predominantly CD4+) and exhibit a highly
cytotoxic activity against autologous tumor cells. The pre-
dominance of CD4+ TIL obtained from human and rat
biopsies contrasts partially to the data reported by Topa-
lian et al. [37]. Indeed, these authors showed a correlation
between CD8+ lymphocytes and high cytotoxic activity.
However, the role of the CD4+ T lymphocyte sub-popula-
tions on the CD8+ TIL activity remains to be clearly
defined. The CD8+ T cell survival and activity against the
most of the tumor is increased by CD4+ T helper cells
(CD4+CD25-) and downregulated by CD4+ T regulator
cells (CD4+CD25+) [38-41]. The CD4+CD25+ T cells
maintain an microenvironment in the tumor sites that
conceal the immunogenicity of tumor to permit progres-
sive growth of antigenic tumors. In such cases, the sup-
pression (in vivo or ex vivo from TIL extracted) of the T
regulator cells represents a possible design of
immunotherapeutic approach. In contrast to these data,
the intestinal tumors which are strongly associated with
an inflammatory microenvironment regress after injec-
tion of CD4+CD25+ T regulator cells [42]. The overall pub-
lished papers raise the possibility of broader functions for
regulatory lymphocytes in prevention and treatment of
human cancers. Thus, CD4+ predominance in TIL popula-
tion could not be prejudicial to the success of T
Proliferation profile of TIL isolated from rat osteosarcomaFigure 5
Proliferation profile of TIL isolated from rat osteosa-
rcoma. These data are representative of three independent 
tumors. TIL isolated from rat osteosarcoma biopsies by 
enzymatic treatment were cultured at 5 × 105 TIL per well 
(6-multiwell plate) for 28 days in X-VIVO 15 supplemented 
with 900 UI/ml IL-2. At day 23 (arrow), 20 × 103 irradiated 
(75 grays) autologous osteosarcoma cells were added in each 
well. TIL were manually numbered using the trypan blue 
staining.
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lymphocyte-based immunotherapy but could be closely
related to their CD25+ (low or high), CD25- status.
The lytic activity exhibited by rat osteosarcoma TIL is
lower against ROS 17/2.8 than against UMR 106 and
autologous tumor cells, suggesting some common tumor
antigens shared by tumor cells. In contrast to the results of
Rivoltini et al. [34], the low proliferation rate of rat TIL
could be easily re-stimulated by autologous tumor anti-
gens (Figure 5). These data therefore revealed that stimu-
lation by tumor antigens could be a more appropriate
technique to expand TIL for their use immunotherapy.
In the past decade, several reports underlined the capabil-
ity of cellular therapy for osteosarcoma. The identification
of human tumor antigens has opened new areas of anti-
gen-specific cancer immunotherapy specifically targeting
these antigens [6]. Indeed, several tumor antigens such as
melanoma-associated antigen (MAGE) [43], squamous
cell carcinoma antigen recognized by T cells (SART) 1
[44], SART3 [45] and papillomavirus binding factor [46]
are expressed in osteosarcoma and provided the rationale
to develop cellular therapies for this pathology. SART3 is
highly expressed in osteosarcoma [45]. Moreover, the
SART3-derived peptides were able to induce HLA-A2-
restricted and tumor-specific cytotoxic T lymphocytes
[45]. These data strengthened the potential use of the
SART3-derived peptides for specific immunotherapy of
HLA-A2+ patients suffering from osteosarcoma. Taken
together with the prevalence of HLA-A24 [46], this strat-
egy could be applicable for approximately 60% of patients
with osteosarcoma. Furthermore, no severe adverse
response associated with peptides administration, and a
significant up-modulation of the cellular immune
response against tumor cells in clinical trial using SART3-
derived peptides in HLA-A24+ patients with colon cancer
[47] encourages further application of this strategy for
osteosarcoma. More recently, Trieb et al. demonstrated
that Hsp 72 is involved in the interaction between T lym-
phocytes and osteosarcoma cells expressing Hsp72 [48].
The cytotoxic potential of these lymphocytes might lead
to an increased immune response leading to the rejection
of the osteosarcoma [48]. In light of the complementary
animal experiments, cytotoxic lymphocytes recognizing
specific tumor antigens appear to be a more effective ther-
apeutic strategy than polyclonal TIL-based immuno-
therapy. Combined TIL with above strategies therefore
might be more effective to achieve desired results.
Conclusion
The results of the present report reveal that TIL exhibiting
a high cytotoxic activity can be easily isolated from adult
osteosarcomas. The poor prognosis of osteosarcoma must
lead to develop new therapeutic approaches, especially in
high sub-group such as adult osteosarcomas. TIL therapy
is one of the hopeful strategies contribute to answer this
intention.
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